Relapsing Multiple Sclerosis Clinical Trial

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS). There is a significant unmet need for therapies that target neuroinflammation in the CNS with a goal of halting long-term disability and neurodegeneration in people with relapsing multiple sclerosis (RMS). Even the most recent disease-modifying therapies act mainly on adaptive immunity in the periphery with only modest or temporary ability to halt neuroinflammatory and neurodegenerative processes and stop disease progression. That’s why the development of MS treatments with new modes of action is of interest.

Beyond the existing strategy to modulate cellular elements of adaptive immunity, there is mounting evidence that innate immunity, mediated by myeloid cell lineages (bone-marrow-derived monocytes/macrophages and CNS-resident microglial cells), is responsible for many of the neurodegenerative aspects of MS that persist in spite of the effectiveness of approved disease-modifying therapies in preventing acute relapses. Immunomodulation directed at innate immunity has potential to curtail “smoldering neuroinflammation” and other manifestations of disease progression that remain unaddressed by current, approved therapies.

Meridian is conducting a clinical research study for an investigational medication for MS.

Eligible participants…

• Are age 18 to 55
• Must be diagnosed with relapsing multiple sclerosis
• Must have:
  • At least 1 documented relapse within the previous year OR
  • 2 or more documented relapses within the previous 2 years OR
  • One or more active Gd-enhancing brain lesion on an MRI scan in the past 6 months
• May receive compensation for time and travel
• Do not need insurance to join this study

For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.

You can also talk to a Meridian enrollment specialist about this study by calling (912) 790-4837.

For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.

Study Location

Meridian Clinical Research
6602 Waters Avenue, Building C
Savannah, GA 31406